Brexit is a critical topic for the medical technology industry which has developed highly complex ties between the United Kingdom (UK) and the rest of the EU. Medical technologies are often moved between different EU countries during their production lifecycle and their clinical use. Crucially, up to 30% of our industry’s products have been authorised via UK Notified Bodies (CE marking) and could lose such authorisation overnight in the case of a “cliff edge” Brexit. MedTech Europe is tracking developments closely and has produced a position paper and other relevant documents to help medtech companies to navigate Brexit.

The medical technology industry is expected to find new ways to keep us healthy, and to do so in a responsible manner. MedTech Europe and its members are committed to a high level of ethical business practices and have put in place strict guidelines to advise medical technology manufacturers on how to collaborate ethically with healthcare professionals (HCPs).

Medical technologies have the potential to save and improve lives, to inform citizens on the state of their health and to guide healthcare delivery.

Medical technologies are tightly regulated in the European Union. Before a medical technology can be legally placed on the EU market, a manufacturer must comply with the requirements of all applicable EU legislation and affix a CE mark to their device.

New EU Regulations governing medical devices (MD) and in vitro diagnostic (IVD) were published in May 2017. MedTech Europe is working with our members and the authorities to support companies in complying with the new legislation by the end of the transition periods – 2020 for MDs and 2022 for IVDs.

The MedTech industry develops products that facilitate the delivery of health services in the community care setting and in people's homes. These technologies save lives, are convenient for patients and make efficient use of healthcare resources.

In addition to the medical technology sector’s core goal of saving lives and improving health, environmental and social considerations are an integral part of our industry’s operations. We acknowledge that preserving a healthy environment and building socially responsible value chains are essential in keeping human beings in good health. Our industry needs to be at the forefront of addressing challenges related to sustainable healthcare.

Information is power. Medical technology companies need to stay on top of the latest trends impacting their business. Informed decisions require up-to-date market intelligence from a trusted service.

Medical technologies generate information and data that are critical for the prevention, diagnosis, treatment, monitoring and management of health and lifestyle. More and more of this data is now digitised; it can be stored and accessed on electronic health records and personal devices, shared among patients and healthcare professionals, and aggregated and processed with data advanced analytics
MedTech Europe works with policymakers and relevant stakeholders to realise the potential of data-driven healthcare. Together we focus on legal and regulatory issues (privacy, safety), technology (cybersecurity, interoperability), the business case (incentives, reimbursement), and emerging technologies (precision medicine, artificial intelligence).

MedTech Europe engages with global agencies, decision-makers and stakeholders on key international issues facing medical technology companies.

Research & Innovation (R&I) is the lifeblood of Europe’s medical technology sector. Industry investment in R&I delivers life-enhancing devices, diagnostics and digital solutions. EU support for R&I offers valuable opportunities for academia and industry to generate new knowledge and use it to tackle the biggest challenges facing our societies. The quest for tomorrow’s healthcare innovations demands new, broad partnerships. R&I is most impactful when it is based on collaboration. MedTech Europe is committed to working with others in the public and private sectors to find shared solutions to our common challenges.

Vision loss can have a profound impact on those affected, resulting in lost independence and significantly limiting daily activities. Ageing increases the risk of eye diseases that can lead to visual impairment. The MedTech industry develops products that reduce the burden of eye disease on individuals, families and the wider economy. These innovations add enormous value to European society.

Antimicrobial Resistance (AMR) and Healthcare Associated Infections (HAI) are among the biggest global public health challenges of our time. These infections cause significant morbidity and mortality, put pressure on health systems, and incur rising direct and indirect costs.
Medical technologies can help to address these problems by preventing, detecting, monitoring and managing infections and resistance.

Cardiovascular diseases can impact millions of people of all ages. Diseases of the heart and circulatory system are the leading cause of death in Europe and a major cause of disability.

The medical technology industry provides high-quality solutions to the burden of cardiovascular diseases on individuals, families and the wider society. These innovations, which span the full spectrum of patient care from diagnosis to cure, save lives and add tremendous value to European society.

Orthopaedics is the medical specialty that focuses on injuries and diseases of the human body's musculoskeletal system. This complex system includes your bones, joints, ligaments, tendons, muscles, and nerves and allows you to move, work, and be active.

The MedTech industry develops products that reduce the burden of musculoskeletal diseases on individuals, families and the wider economy. These innovations improve quality of life and add enormous value to European society.

1 in 11 adults around the world have diabetes. That’s about 60 million people across Europe, equivalent to the total Italian population. This number increases significantly every year. If current trends continue, diabetes will be the number one health threat in the coming years.
The European Diabetes Sector Group aims to reverse this trend by taking meaningful collective action to help avoid the diabetes pandemic where possible, and when diagnosis occurs to put people at the centre of care and give them back a full and fear-free life.
Below you will find our vision, views and resources.